Feedback / Questions
M923 (adalimumab biosimilar) - Momenta
Baxalta: Q4 & FY 2015 Results
(Baxalta)
-
Feb 19, 2016 -
Anticipated dosing of last patient in pivotal P3 trial (NCT02581345) for chronic plaque-type psoriasis in 2016
Anticipated enrollment status
•
Biosimilar
http://s2.q4cdn.com/643609687/files/doc_presentations/2016/feb/BXLT-Q4-2015-Earnings-Release-Presentation-(FINAL).pdf
Feb 19, 2016
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
.